Results 181 to 190 of about 5,435 (219)
Some of the next articles are maybe not open access.

Related searches:

Histamine Sensitization of the Voltage-Gated Sodium Channel Nav1.7 Contributes to Histaminergic Itch in Mice

ACS Chemical Neuroscience, 2022
Itch, a common clinical symptom of many skin diseases, severely impairs the life quality of patients. Nav1.7, a subtype of voltage-gated sodium channels mainly expressed in primary sensory neurons, is responsible for the amplification of threshold currents that trigger action potential (AP) generation.
Shaoheng Li   +8 more
openaire   +2 more sources

Abnormal expression of voltage-gated sodium channels Nav1.7, Nav1.3 and Nav1.8 in trigeminal neuralgia

Neuroscience, 2009
Voltage-gated sodium channels have been implicated in acute and chronic neuropathic pain. Among subtypes, Nav1.7 single mutations can cause congenital indifference to pain or chronic neuropathic pain syndromes, including paroxysmal ones. This channel is co-expressed with Nav1.8, which sustains the initial action potential; Nav1.3 is an embrionary ...
S R D T, Siqueira   +4 more
openaire   +2 more sources

Characterization of a New Class of Potent Inhibitors of the Voltage-Gated Sodium Channel Nav1.7

Biochemistry, 2007
Voltage-gated sodium channels (Nav1) transmit pain signals from peripheral nociceptive neurons, and blockers of these channels have been shown to ameliorate a number of pain conditions. Because these drugs can have adverse effects that limit their efficacy, more potent and selective Nav1 inhibitors are being pursued.
Brande S, Williams   +11 more
openaire   +2 more sources

Selective Ligands and Drug Discovery Targeting the Voltage-Gated Sodium Channel Nav1.7

2018
The voltage-gated sodium (Nav) channel Nav1.7 has been the focus of intense investigation in recent years. Human genetics studies of individuals with gain-of-function and loss-of-function mutations in the Nav1.7 channel have implicated Nav1.7 as playing a critical role in pain.
Jian, Payandeh, David H, Hackos
openaire   +2 more sources

The effect of the voltage-gated sodium channel NaV1.7 blocker PF-05089771 on cough in the guinea pig

Respiratory Physiology & Neurobiology, 2022
Cough in chronic respiratory diseases is a common symptom associated with significant comorbidities including visceral pain. Available antitussive therapy still has limited efficacy. Recent advances in the understanding of voltage-gated sodium channels (NaVs) lead to the rational hypothesis that subtype NaV1.7 is involved in initiating cough and thus ...
Mariana Brozmanova   +3 more
openaire   +2 more sources

Influence of combined voltage-gated sodium channel NaV1.7 and NaV1.8 inhibitors on cough in a guinea pig model

Respiratory Physiology & Neurobiology, 2023
Pathological excessive cough is a serious clinical problem in many patients. It is no doubt that an increased activation and sensitization of airway vagal C-fibres in disease stems from dysregulation of the neural pathways that control cough. Due to the limited efficacy and unwanted side effects of current antitussives, there is a continual demand for ...
Mariana Brozmanova   +4 more
openaire   +2 more sources

The Endocannabinoid Anandamide Inhibits Voltage-Gated Sodium Channels Nav1.2, Nav1.6, Nav1.7, and Nav1.8 in Xenopus Oocytes

Anesthesia & Analgesia, 2014
Anandamide is an endocannabinoid that regulates multiple physiological functions by pharmacological actions, in a manner similar to marijuana. Recently, much attention has been paid to the analgesic effect of endocannabinoids in terms of identifying new pharmacotherapies for refractory pain management, but the mechanisms of the analgesic effects of ...
Dan, Okura   +6 more
openaire   +2 more sources

Identification and characterization of the promoter region of the Nav1.7 voltage-gated sodium channel gene (SCN9A)

Molecular and Cellular Neuroscience, 2008
The Nav1.7 sodium channel plays an important role in pain and is also upregulated in prostate cancer. To investigate the mechanisms regulating physiological and pathophysiological Nav1.7 expression we identified the core promoter of this gene (SCN9A) in the human genome.
James K J, Diss   +4 more
openaire   +2 more sources

Inhibitors of voltage-gated Sodium Channel Na v 1.7: Patent Applications Since 2010

Pharmaceutical Patent Analyst, 2014
There has been intense interest in developing inhibitors of the sodium channel Nav1.7 because genetic studies have established very strong validation for the efficacy to alleviate both inflammatory and neuropathic pain. This review summarizes patent applications targeting Nav1.7 since 2010 until May, 2014.
Shaoyi, Sun   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy